{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:47:12Z","timestamp":1791362832277,"version":"4.3.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1097\/ftd.0000000000000258","type":"journal-article","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T03:37:08Z","timestamp":1445485028000},"page":"274-279","source":"Crossref","is-referenced-by-count":54,"title":["Mycophenolate Mofetil Therapy in Children With Idiopathic Nephrotic Syndrome"],"prefix":"10.1097","volume":"38","author":[{"given":"\u00c1gnes","family":"Hackl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orsolya","family":"Cseprek\u00e1l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Gessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max Christoph","family":"Liebau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Habbig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Ehren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Taylan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"D\u00f6tsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz T.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210129","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","article-title":"Nephrotic syndrome in childhood.","volume":"362","author":"Eddy","year":"2003","journal-title":"Lancet"},{"key":"R2-12-20210129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s004670050555","article-title":"High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood.","volume":"13","author":"Srivastava","year":"1999","journal-title":"Pediatr Nephrol"},{"key":"R3-12-20210129","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1542\/peds.2008-1559","article-title":". Management of childhood onset nephrotic syndrome.","volume":"124","author":"Gipson","year":"2009","journal-title":"Pediatrics"},{"key":"R4-12-20210129","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1053\/ajkd.1998.v31.pm9469489","article-title":"Successful mycophenolate mofetil treatment of glomerular disease.","volume":"31","author":"Briggs","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"R5-12-20210129","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1046\/j.1523-1755.2002.00214.x","article-title":". Mycophenolate mofetil treatment for primary glomerular diseases.","volume":"61","author":"Choi","year":"2002","journal-title":"Kidney Int"},{"key":"R6-12-20210129","first-page":"95A","article-title":"The use of mycophenolate mofetil in children with nephrotic syndrome (Abstract).","volume":"10","author":"Barthos","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R7-12-20210129","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1053\/j.ajkd.2003.08.011","article-title":". Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome.","volume":"42","author":"Bagga","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R8-12-20210129","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s00467-005-1877-x","article-title":". Mycophenolate mofetil in steroidcyclosporine-dependentresistant nephrotic syndrome.","volume":"20","author":"Mendizabal","year":"2005","journal-title":"Pediatr Nephrol"},{"key":"R9-12-20210129","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.00550206","article-title":". Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group.","volume":"1","author":"Hogg","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R10-12-20210129","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00467-008-0899-6","article-title":". Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome.","volume":"23","author":"Dorresteijn","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"R11-12-20210129","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00467-009-1375-7","article-title":". Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome.","volume":"25","author":"Li","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"R12-12-20210129","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00467-011-2006-7","article-title":". Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial.","volume":"27","author":"Baudouin","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"R13-12-20210129","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1681\/ASN.2012121200","article-title":". Gesellschaft fur Padiatrische Nephrologie (GPN). Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome.","volume":"24","author":"Gellermann","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"R14-12-20210129","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00467-003-1300-4","article-title":"Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil.","volume":"19","author":"Gellermann","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"R15-12-20210129","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","article-title":". Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation.","volume":"7","author":"Le Meur","year":"2007","journal-title":"Am J Transpl"},{"key":"R16-12-20210129","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1681\/ASN.V133759","article-title":". The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy.","volume":"13","author":"Weber","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R17-12-20210129","first-page":"163","article-title":"KDIGO clinical practice guideline for Glomerulonephritis.","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"suppl 1","key":"R18-12-20210129","first-page":"10","article-title":". Therapeutisches Drug-Monitoring von Mycophenolat Mofetil bei Kindern mit nephrotischem Syndrom.","volume":"5","author":"Benz","year":"2010","journal-title":"Der Nephrologe"},{"key":"R19-12-20210129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0010-4825(92)90011-B","article-title":"MWPharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring.","volume":"22","author":"Proost","year":"1992","journal-title":"Comput Biol Med"},{"key":"R20-12-20210129","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/FTD.0b013e31818752d9","article-title":". Long-term pharmacokinetics of mycophenolic acid in pediatric renal transplant recipients over 3 years posttransplant.","volume":"30","author":"Weber","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R21-12-20210129","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1681\/ASN.V981511","article-title":". Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.","volume":"9","author":"Weber","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"R22-12-20210129","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/00007691-199412000-00012","article-title":"Blood distribution of mycophenolic acid.","volume":"16","author":"Langman","year":"1994","journal-title":"Ther Drug Monit"},{"key":"R23-12-20210129","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/00365513.2012.745947","article-title":". Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring.","volume":"73","author":"Reine","year":"2013","journal-title":"Scand J Clin Lab Invest"},{"key":"R24-12-20210129","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00467-014-2813-8","article-title":"Therapeutic drug monitoring in pediatric renal transplantation.","volume":"30","author":"Weber","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"R25-12-20210129","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1124\/jpet.103.063073","article-title":". Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats.","volume":"309","author":"Kobayashi","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"R26-12-20210129","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00228-011-1203-4","article-title":". Inosine 5-monophosphate dehydrogenase (IMPDH) activity in childeren: physiological regulation and response to mycophenolic acid (MPA) therapy.","volume":"68","author":"Rother","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"R27-12-20210129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00467-006-0294-0","article-title":". A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome.","volume":"22","author":"Fujinaga","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"R28-12-20210129","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/01.ftd.0000246766.12872.12","article-title":". Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients.","volume":"28","author":"Weber","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R29-12-20210129","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.phrs.2011.01.009","article-title":". Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome.","volume":"63","author":"Saint-Marcoux","year":"2011","journal-title":"Pharmacol Res"},{"key":"R30-12-20210129","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/00007691-199910000-00002","article-title":". Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.","volume":"21","author":"Weber","year":"1999","journal-title":"Ther Drug Monit"},{"key":"R31-12-20210129","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00007890-199907270-00018","article-title":". A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.","volume":"68","author":"van Gelder","year":"1999","journal-title":"Transplantation"},{"key":"R32-12-20210129","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity.","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R33-12-20210129","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/ncpneph0225","article-title":"Histopathology of calcineurin-inhibitor toxicity in renal allografts.","volume":"2","author":"Liptak","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"R34-12-20210129","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1399-0012.2006.00597.x","article-title":". Antifibrotic actions of mycophenolic acid.","volume":"17","author":"Morath","year":"2006","journal-title":"Clin Transpl"},{"key":"R35-12-20210129","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1007\/s004670100006","article-title":". The use of mycophenolate mofetil suspension in pediatric renal allograft recipients.","volume":"16","author":"Bunchman","year":"2001","journal-title":"Pediatr Nephrol"},{"key":"R36-12-20210129","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0041-1345(00)02424-6","article-title":". The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes.","volume":"33","author":"Shipkova","year":"2001","journal-title":"Transpl Proc"},{"key":"R37-12-20210129","first-page":"107","article-title":"Schellhaas U, et al..","volume":"33","author":"Wieland","year":"2000","journal-title":"Induction of cytokine release by acyl glucuronide of mycophenolic acid: a link to side effects Clin Biochem"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T17:47:36Z","timestamp":1653328056000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201604000-00012"}},"subtitle":["Does Therapeutic Drug Monitoring Make a Difference?"],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000258","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}